Navigation Links
The Cancer Market Outlook To 2014: Competitive Landscape, Market Size, Pipeline Analysis and Growth Opportunities Now Available on ReportsandReports
Date:3/11/2010

DALLAS, March 11, 2010 /PRNewswire/ -- ReportsandReports announce it will carry The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities Market Research Report in its Store.

Browse the complete Report on: http://www.reportsandreports.com/market-reports/the-cancer-market-outlook-to-2 014-competitive-landscape-market-/

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.

In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.

At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the premise on which the entire biopharmaceutical industry has been built.

    Key features of this report

    - Epidemiological analysis and forecast prevalence of the major cancer
    indications over the period 2008-14 including lung, breast, colorectal,
    ovarian cancer markets.

    - Forecasts and analysis of the major products in the cancer market over
    the period 2008-14 spread across the major indications and classes of
    treatments.

    - Overview of key events in the global cancer market that have impacted
    treatment trends and sales potential across the major cancer indications.

    - Strategic and growth analysis of leading pharmaceutical corporations
    based on sales focus by drug class, currently marketed products and R&D
    product portfolios.

    Scope of this report

    - Develop insight into patient potential with the report's coverage of
    major indications in the cancer segment, the seven largest geographic
    pharmaceutical markets and 10 largest companies active in the cancer
    segment today

    - Quickly understand how recent events are affecting the performance of
    major products, and how their marketers are confronting competitive
    changes in cancer marketplace

    - Gain up-to-date competitive intelligence across the cancer indications
    and understand the major issues affecting key pharmaceutical/biotech
    players

    - Understand which indications have the greatest potential to provide
    franchise growth, and how pharmaceutical companies are attempting to
    exploit these opportunities


    Key Market Issues
    - FDA approves Cervarix for cervical cancer

In October 2009, FDA approved GSK's Cervarix for the prevention of pre-cancerous lesions caused by human papillomavirus (HPV) type 16 & 18 in women aged 10-25 years. Cervarix's inclusion in children's vaccine program is a major step towards securing reimbursement. Cervarix, expected to launch by the end of 2009, faces direct competition from Merck's Gardasil and will help to reduce the incidence of cervical cancer in future.

- Merck's Gardasil adds US indication of genital warts for boys and men

On 16th October 2009, Gardasil's US label was extended to include its use in both men and boys aged 9-26 years of age. The pivotal trial results showed an efficacy of 90.4% while preventing external genital lesions of HPV types 6/11/16/18. In addition, Merck also planned to extend its vaccine patient assistance program providing free Gardasil to 19-26 year old uninsured males meeting eligibility criteria but unable to afford the vaccine.

    Key findings from this report

    - In 2008, antineoplastic mAbs delivered huge sales of $13.6bn with a
    market share of 28.6% of total sales. The key antineoplastic mAbs which
    contributed to the higher market share of this class in 2008 were
    MabThera (11.0%), Avastin (10.3%), Herceptin (9.7%) and Erbitux (3.4%).
    Forecast sales of the total antineoplastics market are estimated at
    $65.2bn in 2014.

    - Roche is the global market leader in cancer, holding the highest market
    share of 29.2% ($14.0bn sales) in 2008 based on sales from (MabThera,
    Avastin, Herceptin, Tarceva and Xeloda). Roche's strength in the cancer
    market has been bolstered by its acquisition of Genentech and purchase of
    majority stakes in Chugai, which has provided additional breadth to its
    portfolio.

    - Eli Lilly's acquisition of ImClone will increase the former's flow of
    high-quality, innovative new therapies. The transaction will immediately
    enable Eli Lilly to offer physicians and their patients a complementary
    portfolio of leading oncolytic agents and targeted therapies including
    Gemzar, Alimta and Erbitux.

    Key questions answered

    - What will be the major growth indications in the cancer segment over
    the period 2008-14?

    - Which companies were the winners and losers in the cancer segment in
    2008?

    - How have recent major launches from companies such as Roche,
    Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly performed?

    - Which companies will become the key players in the cancer segment over
    the period 2008-14?

    - Which products will be impacted by generic competitors over the period
    2008-14?

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

    Contact:
    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004

    sales@reportsandreports.com

    http://www.reportsandreports.com/


SOURCE MarketsandMarkets

Back to top
'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. febits miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research
2. Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer
3. Partnership to Fight Cancer: CTSciNet and The Damon Runyon Cancer Research Foundation
4. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
5. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
7. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
8. Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer
9. NVHR: Stop Liver Cancer Dead in Its Tracks By Closing Funding Gap for Viral Hepatitis Education, Screening Programs
10. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
11. Life Beyond Cancer Foundation Adds Bob Ingram to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 The research report ... players in the  Global Label-Free Array Systems Market  accounted ... in 2015. Players such as Biacore, Agilent Technologies, ForteBio, ... in the global market due to their unmatched product ... Product upgrades and timely product launches are expected to ...
(Date:12/9/2016)... Dec. 9, 2016 China Cord Blood Corporation (NYSE: ... China,s leading provider of cord blood collection, laboratory ... today announced the results of its 2016 Annual General Meeting, ... S.A.R., China . At ... the re-appointment of KPMG Huazhen LLP as the independent auditors ...
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... This report analyzes the worldwide markets for Biostimulants ... Amino, & Fulvic), Extract Based, and Others. The report also ... & Turf, Row Crops, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and forecasts are ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):